Cue Biopharma Inc. (CUE) Begins Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA (pembrolizumab)

Go back to Cue Biopharma Inc. (CUE) Begins Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA (pembrolizumab)

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

February 8, 2021 8:00 AM EST

CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patients body, announced today that on February 1, 2021, the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Mercks anti-PD-1 therapy, KEYTRUDA®... More